NuGenerex Life Sciences Holdings

NuGenerex Life Sciences Holdings, formerly known as Generex Biotechnology, is a healthcare holding company that operates through several subsidiaries focused on immunotherapy, drug delivery, and diagnostics. The company's core asset is the Ii-Key platform technology, which enhances the potency of peptide vaccines by activating CD4+ T-cells; its lead candidate, AE37, has been evaluated in Phase 2 trials for triple-negative breast cancer and other HER2-expressing malignancies. Additionally, the company developed Oral-lyn, a buccal insulin spray utilizing its proprietary RapidMist delivery system, and Excellagen, an FDA-cleared wound-conforming gel. Despite its diverse pipeline, the company faced severe financial distress, culminating in an involuntary Chapter 7 bankruptcy filing in 2022.